Comparison of treatment outcome between first-line combination immunotherapy (anti-PD-L1 or anti-PD1) with or without chemotherapy and chemotherapy alone in advanced non-small cell lung cancer patients in tertiary care hospital.
Danainut NaratornsirakulBusayamas ChewaskulyongSarawut KongkarnkaSongporn OranratnachaiPublished in: Cancer medicine (2024)
The result of this real-world study in patients with advanced stage NSCLC indicate that first-line immunotherapy-based regimen was associated with significantly greater PFS, OS, and ORR with a safety profile consistent with pivotal studies.
Keyphrases
- advanced non small cell lung cancer
- tertiary care
- end stage renal disease
- epidermal growth factor receptor
- small cell lung cancer
- newly diagnosed
- chronic kidney disease
- ejection fraction
- healthcare
- locally advanced
- peritoneal dialysis
- prognostic factors
- emergency department
- radiation therapy
- chemotherapy induced
- drug induced